These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34217296)

  • 1. Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
    Peng Y; Huang Z; Zhou F; Wang T; Mou K; Feng W
    Cell Commun Signal; 2021 Jul; 19(1):71. PubMed ID: 34217296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
    Chen C; Zhuang Y; Chen X; Chen X; Li D; Fan Y; Xu J; Chen Y; Wu L
    Oncotarget; 2017 Feb; 8(6):10025-10036. PubMed ID: 28036294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
    Woessner DW; Lim CS
    Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.
    Huang ZL; Gao M; Li QY; Tao K; Xiao Q; Cao WX; Feng WL
    Oncotarget; 2013 Dec; 4(12):2249-60. PubMed ID: 24158537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
    Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
    Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
    Wu LX; Xu JH; Zhang KZ; Lin Q; Huang XW; Wen CX; Chen YZ
    Leukemia; 2008 Jul; 22(7):1402-9. PubMed ID: 18418407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
    Li Q; Huang Z; Gao M; Cao W; Xiao Q; Luo H; Feng W
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
    PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
    Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
    Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
    Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
    Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia.
    Zheng R; Wei W; Liu S; Zeng D; Yang Z; Tang J; Tan J; Huang Z; Gao M
    Cell Commun Signal; 2024 Jun; 22(1):314. PubMed ID: 38849885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
    Stella S; Tirrò E; Conte E; Stagno F; Di Raimondo F; Manzella L; Vigneri P
    Mol Cancer Ther; 2013 Jun; 12(6):1085-98. PubMed ID: 23536723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
    Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing the subcellular location of the oncoprotein Bcr-Abl using rationally designed capture motifs.
    Dixon AS; Constance JE; Tanaka T; Rabbitts TH; Lim CS
    Pharm Res; 2012 Apr; 29(4):1098-109. PubMed ID: 22183511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
    Wang J; Huang T; Sun J; Yu Y; Liu Z; Li W; Jia J; Chen C
    Med Oncol; 2014 Aug; 31(8):112. PubMed ID: 25023053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR/ABL mRNA targeting small interfering RNA effects on proliferation and apoptosis in chronic myeloid leukemia.
    Zhu XS; Lin ZY; Du J; Cao GX; Liu G
    Asian Pac J Cancer Prev; 2014; 15(12):4773-80. PubMed ID: 24998540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
    O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
    Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.